尽管精神分裂症的多巴胺假说解释了所有可用的抗精神病药物在临床使用中的作用,越来越需要开发治疗阳性的新药,负,和慢性精神病的认知症状。Xanomeline-trospium(KarXT)是一种药物组合,基于乙酰胆碱在调节认知过程中以及该神经递质与中枢神经系统其他信号通路之间的相互作用中所起的重要作用,在精神分裂症的发病中起着潜在的作用,老年痴呆症,和物质使用障碍。包括四个电子数据库(PubMed,科克伦,Clarivate/WebofScience,和GoogleScholar)和美国国家医学图书馆的临床试验数据库检测到21个来源,这些来源涉及针对KarXT的14项研究,其中只有四个有可用的结果。根据这些试验的结果,黄松松药的短期疗效和耐受性良好,但在该药物组合可能被推荐用于临床之前,还需要更多的数据.然而,在理论层面上,KarXT的探索有助于增加研究人员发现新事物的兴趣,非多巴胺能,可以用作单一疗法或附加药物的抗精神病药。
Although the dopamine hypothesis of schizophrenia explains the effects of all the available antipsychotics in clinical use, there is an increasing need for developing new drugs for the treatment of the positive, negative, and cognitive symptoms of chronic psychoses.
Xanomeline-trospium (KarXT) is a drug combination that is based on the essential role played by acetylcholine in the regulation of cognitive processes and the interactions between this neurotransmitter and other signaling pathways in the central nervous system, with a potential role in the onset of schizophrenia, Alzheimer\'s disease, and substance use disorders. A systematic literature review that included four electronic databases (PubMed, Cochrane, Clarivate/Web of Science, and Google Scholar) and the US National Library of Medicine database for clinical trials detected twenty-one sources referring to fourteen studies focused on KarXT, out of which only four have available results. Based on the results of these trials, the short-term efficacy and tolerability of
xanomeline-trospium are good, but more data are needed before this drug combination may be recommended for clinical use. However, on a theoretical level, the exploration of KarXT is useful for increasing the interest of researchers in finding new, non-dopaminergic, antipsychotics that could be used either as monotherapy or as add-on drugs.